Abstract
About this talk
Ziconotide is a synthetic, water-soluble cone snail venom-derived peptide with a molecular weight of 2,639 Daltons. It is a nonopioid analgesic that selectively binds to N-type voltage-sensitive calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord. This mechanism releases analgesic neurotransmitters into the synaptic gap and subsequently blocks pain signal transmission. Ziconotide does not easily cross the blood-brain barrier, instead revealing its highly potent antinociceptive effect only after intrathecal administration. Because it has a narrow therapeutic window, careful dose titration, and a lag time to allow for onset (and offset) of analgesia and adverse effects are required. The presentation will focus on a recently published consensus proposal and highlight the potential of this drug as well as the areas where additional experience is needed.
Audience Take Away
- Expand the knowledge on possible neuromodulation therapies
- Learn how intrathecal therapy can help patients with chronic pain
- Learn how a non-opioid drug (Ziconotide) could be a viable treatment option
- Learn about the advantages and disadvantages of Ziconotide
- Help physicians provide one more therapy to their chronic pain patients
Speaker
About the speaker
